Posted on 20/11/2009 in Pharmaceutical Company Product News Chugai and Roche have revealed that the drug they developed in cooperation, RoACTEMRA, (tocilizumab) yielded a successful outcome as part of a recent study.
The product successfully met its primary endpoint in a paediatric study of systemic onset Juvenile Idiopathic Arthritis (sJIA) of noticeably curbing symptoms of the disease.
According to the companies, this is particularly good news for child sufferers, as there is currently no approved treatment available for the condition.
Some of the symptoms of sJIA include rashes, fever, infections and anaemia.
William Burns, chief executive of Roche's pharmaceuticals division, explained: "This is a particularly debilitating disease affecting the entire body in which morbidity is high and there is much need for new treatment options in this area."
In other Chugai news, the firm revealed earlier this month that its product Avastin has been approved by the ministry of health, labour and welfare to treat unresectable advanced or recurrent non-squamous non-small cell lung cancer.
Other news stories from 20/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
